Search Result

Isoforms Recommended:	CXCR2

Results for "

CXCR2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CCR (1) CX3CR1 (1) CXCR (41) Drug Metabolite (2) Endogenous Metabolite (2) Fungal (2) Interleukin Related (3) Oxidative Phosphorylation (1) Protein Arginine Deiminase (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (17) Endocrinology (14) Infection (3) Inflammation/Immunology (33) Metabolic Disease (1) Neurological Disease (2)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147392

CXCR2 antagonist 8

CXCR Metabolic Disease

CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .

CXCR2 antagonist 8	CXCR	Metabolic Disease
CXCR2 antagonist 8 is a potent and selective *CXCR2* antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .

HY-144784

CXCR2 antagonist 7	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 7 (compound 19) is a potent *CXCR2* antagonist. CXCR2 antagonist 7 shows potent *CXCR2* binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144781

CXCR2 antagonist 5	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 5 (compound 25) is a potent *CXCR2* antagonist. CXCR2 antagonist 5 shows potent *CXCR2* binding affinity (IC₅₀=0.013 µM) and calcium mobilization (IC₅₀=0.1 µM) ^{[ 1]}.

HY-144783

CXCR2 antagonist 6	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 6 (compound 35c) is a potent *CXCR2* antagonist. CXCR2 antagonist 6 shows potent *CXCR2* binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-139874

CXCR2 antagonist 3	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3 ⁺ T lymphocytes into the Pan02 tumor tissues .

HY-139873

CXCR2 antagonist 2

CXCR Cancer

CXCR2 antagonist 2 is a potent CXCR2 antagonist for cancer immunoresearch with an IC₅₀ value of 95 nM.

CXCR2 antagonist 2	CXCR	Cancer
CXCR2 antagonist 2 is a potent *CXCR2* antagonist for cancer immunoresearch with an IC₅₀ value of 95 nM.

HY-144780

CXCR2 antagonist 4	CXCR	Cancer
CXCR2 antagonist 4 (compound 7) is a potent *CXCR2* antagonist with an IC₅₀ value of 0.13 μM. CXCR2 antagonist 4 can inhibit CXCL8-induced cytosolic calcium increase (IC₅₀ = 27 μM). CXCR2 antagonist 4 can be used for researching anticancer .

HY-D2310

CXCR2 Probe 1	CXCR	Inflammation/Immunology
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for *CXCR2* and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-RS03400

CXCR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR2 Human Pre-designed siRNA Set A CXCR2 Human Pre-designed siRNA Set A

HY-RS03401

Cxcr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr2 Mouse Pre-designed siRNA Set A Cxcr2 Mouse Pre-designed siRNA Set A

HY-RS03402

Cxcr2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cxcr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr2 Rat Pre-designed siRNA Set A Cxcr2 Rat Pre-designed siRNA Set A

HY-101022

CXCR2-IN-1

2 Publications Verification

CXCR Inflammation/Immunology Endocrinology

CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonist with a pIC₅₀ of 9.3.

CXCR2-IN-1 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
CXCR2-IN-1 is a central nervous system penetrant *CXCR2* antagonist with a pIC₅₀ of 9.3.

HY-120878

CXCR2-IN-2 1 Publications Verification	CXCR	Inflammation/Immunology
CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable *CXCR2* antagonist (IC₅₀=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC₅₀ of 0.04 μM .

HY-120878A

*(R,R)-CXCR2-IN-2*	CXCR	Inflammation/Immunology
(R,R)-CXCR2-IN-2, diastereoisomer of CXCR2-IN-2 (compound 68), is a brain penetrant *CXCR2* antagonist with a pIC₅₀ of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively .

HY-149096

CCR7 antagonist 1

CXCR Others

CCR7 antagonist 1 (30c) is a dual CXCR2 (IC₅₀ of 11.02 μM) and CCR7 (IC₅₀ of 0.43 μM) antagonist .

CCR7 antagonist 1	CXCR	Others
CCR7 antagonist 1 (30c) is a dual *CXCR2* (IC₅₀ of 11.02 μM) and CCR7 (IC₅₀ of 0.43 μM) antagonist .

HY-145640

Vimnerixin AZD4721; RIST4721	CXCR	Inflammation/Immunology
Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease .

HY-16711

SB225002 30+ Cited Publications	CXCR	Inflammation/Immunology Endocrinology Cancer
SB225002, a potent, selective and non-peptide *CXCR2* antagonist, inhibits ¹²⁵I-IL-8 binding to CXCR2 with an IC₅₀ of 22 nM.

HY-155698

Mz438

Others Others

Mz438 is high-affinity and selective fluorescent CXCR2 ligand. Mz438 is a small-molecule-based fluorescent probe targeting the IABS of CXCR2 .

Mz438	Others	Others
Mz438 is high-affinity and selective fluorescent CXCR2 ligand. Mz438 is a small-molecule-based fluorescent probe targeting the IABS of CXCR2 .

HY-N2573A

Corydalmine hydrochloride L-Corydalmine hydrochloride; TLZ-16-CL	Fungal CXCR	Infection Neurological Disease
Corydalmine hydrochloride inhibits spore germination of some plant pathogenic as well as saprophytic fungi . Corydalmine hydrochloride acts as an oral analgesic agent, exhibiting potent analgesic activity ^[2]. Corydalmine hydrochloride alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway .

HY-10198

Navarixin 20+ Cited Publications SCH 527123; MK-7123	CXCR	Inflammation/Immunology Endocrinology Cancer
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both *CXCR1* and *CXCR2, with K_d* values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly ^[2].

HY-13021

SRT3190

CXCR Inflammation/Immunology Endocrinology

SRT3190 is an antagonist of CXCR2, used in the research of chemokine mediated diseases.
HY-19768

Danirixin

5+ Cited Publications

GSK1325756
CXCR Inflammation/Immunology Endocrinology

Danirixin is a selective, and reversible CXCR2 antagonist, with IC₅₀ of 12.5 nM for CXCL8.
HY-19855

AZD-5069

5+ Cited Publications

CXCR Endocrinology Cancer

AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

SRT3190	CXCR	Inflammation/Immunology Endocrinology
SRT3190 is an antagonist of *CXCR2*, used in the research of chemokine mediated diseases.

Danirixin 5+ Cited Publications GSK1325756	CXCR	Inflammation/Immunology Endocrinology
Danirixin is a selective, and reversible *CXCR2* antagonist, with IC₅₀ of 12.5 nM for CXCL8.

AZD-5069 5+ Cited Publications	CXCR	Endocrinology Cancer
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

HY-101407

Nicotinamide N-oxide	Oxidative Phosphorylation CXCR Drug Metabolite Endogenous Metabolite	Inflammation/Immunology Endocrinology
Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

HY-15462

SRT3109 1 Publications Verification AZD-5122	CXCR	Inflammation/Immunology Endocrinology
SRT3109 is an antagonist of *CXCR2, with a pIC₅₀* of 8.2, and used in the research of chemokine mediated diseases.

HY-16981

SB-332235	CXCR	Inflammation/Immunology
SB-332235 is a potent, orally active nonpeptide *CXCR2* antagonist, with an IC₅₀ of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells ^[2].

HY-18263A

Elubrixin SB-656933	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active *CXCR2* antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation ^[2] .

HY-18263C

Elubrixin tosylate SB-656933 tosylate	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active *CXCR2* antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation ^[2] .

HY-18263

Elubrixin hydrochloride SB-656933 hydrochloride	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active *CXCR2* antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation ^[2] .

HY-15251

Reparixin Maximum Cited Publications 49 Publications Verification Repertaxin; DF 1681Y	CXCR	Inflammation/Immunology Endocrinology Cancer
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors *CXCR1* and *CXCR2* activation with IC₅₀s of 1 and 100 nM, respectively.

HY-10011

SCH 563705 3 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
SCH 563705 is a potent and orally available *CXCR2* and *CXCR1* antagonist, with IC₅₀s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively.

HY-19519A

Ladarixin sodium 1 Publications Verification DF 2156A	CXCR	Infection Inflammation/Immunology
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual *CXCR1* and *CXCR2* antagonist. Ladarixin sodium can be used for the research of COPD and asthma .

HY-119259

AZD8309	CXCR	Inflammation/Immunology
AZD8309 is an orally active antagonist of *CXCR2*. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases .

HY-19519

Ladarixin 1 Publications Verification DF 2156A free base	CXCR	Inflammation/Immunology Cancer
Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual *CXCR1* and *CXCR2* antagonist. Ladarixin can be used for the research of COPD and asthma .

HY-101407R

Nicotinamide N-oxide (Standard)	CXCR Drug Metabolite Endogenous Metabolite	Inflammation/Immunology Endocrinology
Nicotinamide N-oxide (Standard) is the analytical standard of Nicotinamide N-oxide. This product is intended for research and analytical applications. Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

HY-13848

AZD8797 10+ Cited Publications KAND567	CX3CR1 CXCR	Inflammation/Immunology Endocrinology
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with K_is of 3.9 and 2800 nM, respectively .

HY-15251A

(Rac)-Reparixin (Rac)-Repertaxin; (Rac)-DF 1681Y	Others	Inflammation/Immunology Endocrinology Cancer
(Rac)-Reparixin is the isomer of Reparixin (HY-15251), and can be used as an experimental control. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors *CXCR1* and *CXCR2* activation with IC₅₀s of 1 and 100 nM, respectively.

HY-119339

SX-682 5 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
SX-682 is an orally bioavailable, potent allosteric inhibitor of *CXCR1* and *CXCR2*. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity .

HY-162505

SQA1	CCR CXCR	Inflammation/Immunology Cancer
SQA1, a squaramide (SQA) derivative, is a CCR6 antagonist with a K_d of 250 nM. SQA1 is also a *CXCR2* inhibitor. The intracellular pocket occupied by SQA1 overlaps with the G protein binding site and stabilizes the closed conformation of the intracellular pocket .

HY-N2573

Corydalmine L-Corydalmine; TLZ-16	Fungal CXCR	Infection Neurological Disease
Corydalmine (L-Corydalmine) inhibits spore germination of some plant pathogenic as well as saprophytic fungi . Corydalmine acts as an oral analgesic agent, exhibiting potent analgesic activity ^[2]. Corydalmine alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway .

HY-153450

JBI-589	Protein Arginine Deiminase	Cancer
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors .

HY-163475

*CXCL-CXCR1/2-IN-1*	CXCR	Cancer
CXCL-CXCR1/2-IN-1 is an orally active ELR ⁺CXCL-CXCR1/2 pathway inhibitor with an EC₅₀ of 42.7 nM for CXCR2 . CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects .

HY-50688

SB-265610 2 Publications Verification	CXCR	Inflammation/Immunology
SB-265610 is a selective, competitive, nonpeptide and allosteric *CXCR2* antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC₅₀s of 3.7 nM and 70 nM, respectively ^[2].

HY-124056

AZ10397767	CXCR	Cancer
AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC₅₀ of 1 nM. AZ10397767 attenuates the Oxaliplatin (HY-17371)-induced NF-κB transcriptional activity and potentiates Oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells. AZ10397767 significantly inhibits neutrophil recruitment into tumors which then adversely affects tumor growth in vitro and in vivo ^[2] .

HY-P4846

Ac-Pro-Gly-Pro-OH	CXCR	Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as *CXCR2* agonist. Ac-Pro-Gly-Pro-OH elicits bactericidal activity and inhibits lung inflammation, reducing immune cell apoptosis. Ac-Pro-Gly-Pro-OH enhances the production of type 1 cytokines (IFN-γ and IL-12) but inhibits the production of proinflammatory cytokines. Ac-Pro-Gly-Pro-OH has the potential for the research of sepsis ^[2].

HY-12927

SX-517	CXCR	Inflammation/Immunology
SX-517 is a dual *CXCR2/1* antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca ²⁺ flux (IC₅₀=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC₅₀=60 nM) and *ERK1/2* phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model ^[2].

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury ^[2] .

Cat. No.	Product Name	Type

HY-D2310

CXCR2 Probe 1

Dyes

CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

Cat. No.	Product Name	Target	Research Area

HY-P4846

Ac-Pro-Gly-Pro-OH	CXCR	Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as *CXCR2* agonist. Ac-Pro-Gly-Pro-OH elicits bactericidal activity and inhibits lung inflammation, reducing immune cell apoptosis. Ac-Pro-Gly-Pro-OH enhances the production of type 1 cytokines (IFN-γ and IL-12) but inhibits the production of proinflammatory cytokines. Ac-Pro-Gly-Pro-OH has the potential for the research of sepsis ^[2].

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury ^[2] .

Recombinant Proteins Recommended:

CXCR2

Species:	Human (2) Mouse (1)
Tag:	His (3) SUMO (1)
Source:	E. coli Cell-free (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P790083

CXCR2 Protein, Human (Cell-Free, His)

CXC-R2; CXCR-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B (IL-8R B); IL-8 receptor type 2; CXCR2; IL8RB
Human E. coli Cell-free

HY-P700536

	CXCR2 Protein, Human (His-SUMO) C-X-C motif chemokine receptor 2; IL8RB, interleukin 8 receptor, beta; C-X-C chemokine receptor type 2; CD182; CMKAR2	Human	E. coli
	CXCR2, the receptor for interleukin-8 (IL-8), orchestrates neutrophil activation through a G-protein-mediated phosphatidylinositol-calcium second messenger system upon IL-8 binding. Exhibiting high-affinity binding to IL-8, CXCR2 also interacts with other ligands like CXCL3, GRO/MGSA, and NAP-2. The involvement of GNAI2 underscores the intricate signaling mechanisms regulating neutrophil function through CXCR2. CXCR2 Protein, Human (His-SUMO) is the recombinant human-derived CXCR2 protein, expressed by E. coli, with N-SUMO, N-6*His labeled tag. The total length of CXCR2 Protein, Human (His-SUMO) is 40 a.a., with molecular weight of 20.6 kDa.

HY-P702257

	CXCR2 Protein, Mouse (Cell-Free, His) C-X-C chemokine receptor type 2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8R B; CD182	Mouse	E. coli Cell-free
	CXCR2 protein acts as a receptor for interleukin-8 and induces neutrophil activation through the G protein-mediated phosphatidylinositol-calcium second messenger system. In addition to IL-8, CXCR2 also exhibits high-affinity binding to ligands such as CXCL3, GRO/MGSA, and NAP-2. CXCR2 Protein, Mouse (Cell-Free, His) is the recombinant mouse-derived CXCR2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of CXCR2 Protein, Mouse (Cell-Free, His) is 359 a.a., with molecular weight of 43.2 kDa.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81158

	CXCR2 Antibody CXC-chemokine receptor 2; CD 182; CD182; CD182 antigen; CDw128b; Chemokine (CXC) receptor 2; CMKAR2; CXCR 2; CXC R2; CXC-R2; CXCR2_HUMAN; C-X-C chemokine receptor type 2; CXCR-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8R B; IL-8 receptor type 2.	WB, IHC-P, ELISA	Human
	CXCR2 Antibody is an unconjugated, approximately 41 kDa, rabbit-derived, anti-CXCR2 polyclonal antibody. CXCR2 Antibody can be used for: WB,IHC-P ELISA expriments in human background without labeling.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks